Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection

References

• Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol. 2005;17:447–455.
   PubMed Web of Science ®Google Scholar
• Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995;123:615–620.
   PubMed Web of Science ®Google Scholar
• Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology. 2006;44:15–22.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348–360.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Muñoz S, Medina F, et al.; HISPAMEC Study Group. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol. 2009;36:1442–1448.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Trejo O, García-Carrasco M, et al. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford). 2003;42:818–828.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Commarmond C, Sadoun D, et al. Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents. Rheum Dis Clin North Am. 2017;43:123–132.
   PubMed Web of Science ®Google Scholar
• Ferri C, Ramos-Casals M, Zignego AL, et al.; ISG-EHCV coauthors. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145–1160.
   PubMed Web of Science ®Google Scholar
• Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61:S69–S78.
   PubMed Web of Science ®Google Scholar
• Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150:145–155.
   PubMed Web of Science ®Google Scholar
• Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48:105–111.
   PubMedGoogle Scholar
• Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol Hematol. 2015;93:246–256.
   PubMed Web of Science ®Google Scholar
• Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–2017.
   PubMed Web of Science ®Google Scholar
• Tasleem S, Sood GK. Hepatitis C associated B-cell non-Hodgkin lymphoma: clinical features and the role of antiviral therapy. J Clin Transl Hepatol. 2015;3:134–139.
   PubMedGoogle Scholar
• Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128:2527–2532.
   PubMed Web of Science ®Google Scholar
• Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol. 2015;21:11974–11983.
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790–800.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir and velpatasvir combination improves outcomes reported by patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017;15:421–430.e6.
   Web of Science ®Google Scholar
• Neary MP, Cort S, Bayliss MS, et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19:77–85.
   PubMed Web of Science ®Google Scholar
• Isaacs D, Abdelaziz N, Keller M, et al. Measuring the response of extrahepatic symptoms and quality of life to antiviral treatment in patients with hepatitis C. Hepat Res Treat. 2013;2013:910519.
   PubMedGoogle Scholar
• Zignego AL, Ramos-Casals M, Ferri C, et al.; ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16:523–541.
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Lindahl K, Ståhle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003;18:1573–1580.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Ariello M, et al. The use of interferon-alpha in a small cohort of patients with a type of idiopathic pulmonary fibrosis, probably post-cryoglobulinaemia, hepatitis C virus related. Eur J Gastroenterol Hepatol. 2005;17:1439–1440.
   PubMed Web of Science ®Google Scholar
• Fernández I, Castellano G, de Salamanca RE, et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol. 2003;38:314–319.
   PubMed Web of Science ®Google Scholar
• Furuta M, Kaito M, Gabazza E, et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol. 2000;35:60–62.
   PubMed Web of Science ®Google Scholar
• Esmail ES, Asal FH, Yussif M, et al. Low dose ribavirin has been effective in the treatment of incapacitating muco-cutaneous extrahepatic manifestations in patients with hepatitis C with contraindication or no access for approved antiviral treatment. Arab J Gastroenterol. 2015;16:125–128.
   PubMed Web of Science ®Google Scholar
• Doffoël-Hantz V, Loustaud-Ratti V, Ramos-Casals M, et al. Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev Med Interne. 2005;26:88–94.
   PubMed Web of Science ®Google Scholar
• Chen MH, Chen MH, Tsai CY, et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus. 2015;24:1029–1036.
   PubMed Web of Science ®Google Scholar
• Onishi S, Nagashima T, Kimura H, et al. Systemic lupus erythematosus and Sjögren’s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus. 2010;19:753–755.
   PubMed Web of Science ®Google Scholar
• Venezia G, Licata A, Di Marco V, et al. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis. 2005;37:882–885.
   PubMedGoogle Scholar
• Tahara H, Kojima A, Hirokawa T, et al. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med. 2007;46:473–476.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Terrier B, Semoun O, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken). 2011;63:427–435.
   PubMed Web of Science ®Google Scholar
• Retamozo S, Díaz-Lagares C, Bosch X, et al. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013;92:273–284.
   PubMed Web of Science ®Google Scholar
• Trejo O, Ramos-Casals M, García-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252–262.
   PubMed Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355–374.
   PubMed Web of Science ®Google Scholar
• Della Rossa A, Tavoni A, D’Ascanio A, et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol. 2010;39:167–170.
   PubMed Web of Science ®Google Scholar
• Rieu V, Cohen P, André MH, et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford). 2002;41:290–300.
   PubMed Web of Science ®Google Scholar
• Wener MH, Hutchinson K, Morishima C, et al. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum. 2004;50:2305–2308.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fabbrizzi A, Triboli E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis. 2014;46:833–837.
   PubMedGoogle Scholar
• Saadoun D, Resche Rigon M, Pol S, et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62:24–30.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777–1782.
   PubMed Web of Science ®Google Scholar
• Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–417.
   PubMed Web of Science ®Google Scholar
• Bonacci M, Lens S, Londoño MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15:575-583.e1.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Piluso A, Urraro T, et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets. 2016 Feb 8. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101:3827–3834.
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101:3818–3826.
   PubMed Web of Science ®Google Scholar
• Cavallo R, Roccatello D, Menegatti E, et al. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol. 2009;256:1076–1082.
   PubMed Web of Science ®Google Scholar
• Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116:335–342.
   PubMed Web of Science ®Google Scholar
• Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10:714–719.
   PubMed Web of Science ®Google Scholar
• Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 Plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol. 2016;43:251–260.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67:1431–1436.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116:343–353.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326–334; quiz 504–505.
   Web of Science ®Google Scholar
• Bryce AH, Dispenzieri A, Kyle RA, et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma. 2006;7:140–144.
   PubMedGoogle Scholar
• Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med. 2015;127:413–417.
   PubMed Web of Science ®Google Scholar
• Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11:48–55.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–853.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Iwata T, Haga T, et al. Eradication of hepatitis C virus could improve immunological status and pyoderma gangrenosum-like lesions. Hepatol Res. 2014;44:238–245.
   PubMed Web of Science ®Google Scholar
• Sene D, Ghillani-Dalbin P, Thibault V, et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol. 2004;31:2199–2206.
   PubMed Web of Science ®Google Scholar
• Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore). 2002;81:398–409.
   PubMed Web of Science ®Google Scholar
• Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618–623.
   PubMed Web of Science ®Google Scholar
• Pansini F, Bonifati C, Manno C, et al. Rituximab induces complete remission in a case of membranous nephropathy associated with hepatitis C virus-related infection. Nephrol Dial Transplant. 2007;22:3674–3676.
   PubMed Web of Science ®Google Scholar
• Ji F, Li Z, Ge H, et al. Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Intern Med. 2010;49:2531–2532.
   PubMed Web of Science ®Google Scholar
• Gemignani F, Melli G, Inglese C, et al. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst. 2002;7:59–64.
   PubMed Web of Science ®Google Scholar
• Nemni R, Sanvito L, Quattrini A, et al. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry. 2003;74:1267–1271.
   PubMed Web of Science ®Google Scholar
• Lidove O, Cacoub P, Maisonobe T, et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis. 2001;60:290–292.
   PubMed Web of Science ®Google Scholar
• Santoro L, Manganelli F, Briani C, et al.; HCV Peripheral Nerve Study Group. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. J Neurol Neurosurg Psychiatry. 2006;77:626–629.
   PubMed Web of Science ®Google Scholar
• Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis. 2013;72:374–380.
   PubMed Web of Science ®Google Scholar
• Néel A, Masseau A, Hervier B, et al. Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab. J Clin Rheumatol. 2011;17:439–441.
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Fazzi P, et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol. 1997;36:360–365.
   PubMedGoogle Scholar
• Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders - a review. J Adv Res. 2017;8:139–148.
   PubMed Web of Science ®Google Scholar
• Fletcher NF, Wilson GK, Murray J, et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology. 2012;142:634–643.e6.
   PubMed Web of Science ®Google Scholar
• Dufour JF, Pradat P, Ruivard M, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol. 2009;21:245–253.
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol. 2000;18:579–584.
   PubMed Web of Science ®Google Scholar
• Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005;44:1016–1020.
   PubMed Web of Science ®Google Scholar
• Fadda P, La Civita L, Zignego AL, et al. Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome. Reumatismo. 2002;54:316–323.
   PubMedGoogle Scholar
• Ramos-Casals M, Zignego AL, Ferri C, et al.; International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV). Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66:1282–1299.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Masolini P, et al. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy. Clin Exp Rheumatol. 2013;31:S9–S14.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Corazza L, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford). 2014;53:2209–2213.
   PubMed Web of Science ®Google Scholar